Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico

Samuel Ponce-de-León, Martha Torres, Luis Enrique Soto-Ramírez, Juan José Calva, Patricio Santillán-Doherty, Dora Eugenia Carranza-Salazar, Juan Manuel Carreño, Claudia Carranza, Esmeralda Juárez, Laura E. Carreto-Binaghi, Luis Ramírez-Martínez, Georgina Paz De la Rosa, Rosalía Vigueras-Moreno, Alejandro Ortiz-Stern, Yolanda López-Vidal, Alejandro E. Macías, Jesús Torres-Flores, Oscar Rojas-Martínez, Alejandro Suárez-Martínez, Gustavo Peralta-Sánchez, Hisaaki Kawabata, Irene González-Domínguez, José Luis Martínez-Guevara, Weina Sun, David Sarfati-Mizrahi, Ernesto Soto-Priante, Héctor Elías Chagoya-Cortés, Constantino López-Macías, Felipa Castro-Peralta, Peter Palese, Adolfo García-Sastre, Florian Krammer, Bernardo Lozano-Dubernard

Open source

DOI: 10.1038/s41541-023-00662-6
Published: 2023-05-10
Container: npj Vaccines
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41541-023-00662-6,
  title = {Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico},
  author = {Samuel Ponce-de-León and Martha Torres and Luis Enrique Soto-Ramírez and Juan José Calva and Patricio Santillán-Doherty and Dora Eugenia Carranza-Salazar and Juan Manuel Carreño and Claudia Carranza and Esmeralda Juárez and Laura E. Carreto-Binaghi and Luis Ramírez-Martínez and Georgina Paz De la Rosa and Rosalía Vigueras-Moreno and Alejandro Ortiz-Stern and Yolanda López-Vidal and Alejandro E. Macías and Jesús Torres-Flores and Oscar Rojas-Martínez and Alejandro Suárez-Martínez and Gustavo Peralta-Sánchez and Hisaaki Kawabata and Irene González-Domínguez and José Luis Martínez-Guevara and Weina Sun and David Sarfati-Mizrahi and Ernesto Soto-Priante and Héctor Elías Chagoya-Cortés and Constantino López-Macías and Felipa Castro-Peralta and Peter Palese and Adolfo García-Sastre and Florian Krammer and Bernardo Lozano-Dubernard},
  year = {2023},
  journal = {npj Vaccines},
  doi = {10.1038/s41541-023-00662-6},
  url = {https://doi.org/10.1038/s41541-023-00662-6}
}

RIS

TY  - JOUR
TI  - Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico
AU  - Samuel Ponce-de-León
AU  - Martha Torres
AU  - Luis Enrique Soto-Ramírez
AU  - Juan José Calva
AU  - Patricio Santillán-Doherty
AU  - Dora Eugenia Carranza-Salazar
AU  - Juan Manuel Carreño
AU  - Claudia Carranza
AU  - Esmeralda Juárez
AU  - Laura E. Carreto-Binaghi
AU  - Luis Ramírez-Martínez
AU  - Georgina Paz De la Rosa
AU  - Rosalía Vigueras-Moreno
AU  - Alejandro Ortiz-Stern
AU  - Yolanda López-Vidal
AU  - Alejandro E. Macías
AU  - Jesús Torres-Flores
AU  - Oscar Rojas-Martínez
AU  - Alejandro Suárez-Martínez
AU  - Gustavo Peralta-Sánchez
AU  - Hisaaki Kawabata
AU  - Irene González-Domínguez
AU  - José Luis Martínez-Guevara
AU  - Weina Sun
AU  - David Sarfati-Mizrahi
AU  - Ernesto Soto-Priante
AU  - Héctor Elías Chagoya-Cortés
AU  - Constantino López-Macías
AU  - Felipa Castro-Peralta
AU  - Peter Palese
AU  - Adolfo García-Sastre
AU  - Florian Krammer
AU  - Bernardo Lozano-Dubernard
PY  - 2023
JO  - npj Vaccines
DO  - 10.1038/s41541-023-00662-6
UR  - https://doi.org/10.1038/s41541-023-00662-6
ER  -

APA

Ponce-de-León, S., Torres, M., Soto-Ramírez, L. E., Calva, J. J., Santillán-Doherty, P., Carranza-Salazar, D. E., Carreño, J. M., Carranza, C., Juárez, E., Carreto-Binaghi, L. E., Ramírez-Martínez, L., Rosa, G. P. D. L., Vigueras-Moreno, R., Ortiz-Stern, A., López-Vidal, Y., Macías, A. E., Torres-Flores, J., Rojas-Martínez, O., Suárez-Martínez, A., Peralta-Sánchez, G., Kawabata, H., González-Domínguez, I., Martínez-Guevara, J. L., Sun, W., Sarfati-Mizrahi, D., Soto-Priante, E., Chagoya-Cortés, H. E., López-Macías, C., Castro-Peralta, F., Palese, P., García-Sastre, A., Krammer, F., & Lozano-Dubernard, B. (2023). Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico. npj Vaccines. https://doi.org/10.1038/s41541-023-00662-6

Source records

crossref · retrieved 2026-09-27T05:04:48.637Z